Article

In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies

2024-01-31

Abstract excerpt

<title>Abstract</title> <p>Anti-CD19/CD3 bispecific T-cell engagers (CD19BiTE) has shown promising efficacy in patients with relapsed or refractory (r/r) B-cell malignancies. However, the short half-life of CD19BiTE necessitates long-term repeated administration with rest period, which not only increases the costs but also compromises the efficacy. Long-term and stable expression of CD19BiTE is crucial for achiev...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 51da4c83-5903-56bb-ab6d-ab412b6095c7
DOI: 10.21203/rs.3.rs-3891067/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignanciesDOI 10.21203/rs.3.rs-3891067/v1Read

CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity Read

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read

Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearanceSemantic proximity Read

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read

CAR therapy: the CD19 paradigmSemantic proximity Read

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read

Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engagerSemantic proximity Read

Preferential disruption of HLA-A/B enhances allogeneic CAR-T cell expansion and antitumor capacity in B cell malignanciesSemantic proximity Read

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALLSemantic proximity Read

Cancer cell-selective ecotopic expression of CD20 as an antigen enables rituximab repurposing for solid tumor immunotherapySemantic proximity Read